Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia
Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division
Emerging Trends in PBM Restrictions on Commercial Copay Assistance
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Top Trends in Health Policy in Canada: Insights from InnomarLive
Rethink: Payer Strategies for Commercializing Cell and Gene Therapies
Insights from managed care executives on the future of coverage and outcomes evaluation.
HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients